Oxford BioMedica Handed Back Trovax® and Secures Ocular Disease Deal
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 5 (Table of Contents)
Published: 1 May-2009
DOI: 10.3833/pdr.v2009.i5.1105 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Oxford BioMedica’s cancer vaccine was a victim of Sanofi-aventis’ portfolio review after the French pharma company handed back rights to Trovax® ten months after it failed in a late stage clinical trial...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS